11.12.2009 • News

Personnel Change At Morphosys

Morphosys announced the appointment of Lisa Rojkjaer, MD, as Vice President and Head of Clinical Development. 
Dr. Rojkjaer joins Morphosys from Novartis Pharma where she most recently held the position of Head of Medical Affairs - Hematology, Europe, following her appointment as global clinical program head for Exjade. Here she was responsible for all clinical activities in Europe for Novartis's Hematology portfolio including Gleevec and Exjade. Prior to her tenure at Novartis, she spent five years with Novo Nordisk, in Copenhagen, Denmark, and Princeton, U.S. as the Director of Global Medical Affairs Biopharmaceuticals and later Director, Clinical Development Hematology.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.